Kiniksa Pharmaceuticals International, plc has grown revenue 47% a year over three years and 105% a year over five, with earnings per share compounding at −31%. Revenue growth, 3-year annual rate: +47% (Drug Manufacturers - Specialty & Generic median +15%). Revenue growth, 5-year rate: +105%, growth has slowed since the five-year average. Earnings per share, 3-year rate: −31%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 9, FY2017 to FY2025, as filed.

KNSAKiniksa Pharmaceuticals International, plc

HealthcareUSD

$78.72

$32.1552 weeks$80.83

Is it growing?

Is KNSA growing?

Kiniksa Pharmaceuticals International, plc has grown revenue 47% a year over three years and 105% a year over five, with earnings per share compounding at −31%.

+47%

Revenue growth, 3-year annual rate · Drug Manufacturers - Specialty & Generic median +15% · compounding fast · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +105%
Revenue growth, 5-year rate · +47% over three · growth has slowed since the five-year average
Earnings per share, 3-year rate: −31%
Earnings per share, 3-year rate · revenue +47% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 9
Years of annual history on file · FY2017 to FY2025, as filed